Back to Screener

Healthcare

Penumbra, Inc.(PEN)

Live Price

Offline

$318.71

+0.12% today

1Y Change

+25.05%

Window

Jun 23, 2025 โ†’ Jun 15, 2026

Market Cap
$12.77B
Revenue Growth
+17.5%
EPS Growth
+1169.4%
Dividend Yield
0.0%

Coverage: 246 bars ยท Jun 23, 2025 โ†’ Jun 15, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Penumbra, Inc. (PEN) is a Healthcare stock with a market cap of $12.77B and listed on NYSE. The stock last traded around $318.71 and up 25.1% across the available one-year price window (Jun 23, 2025 โ†’ Jun 15, 2026). Baseline metrics include revenue growth of +17.5%, EPS growth of +1169.4%, a dividend yield of 0.0%. What stands out right now is revenue +17.5%, EPS +1169.4%, free cash flow +18.8% with operating margin 13.5% and ROIC 9.9%. Valuation already assumes a fairly strong business story at P/E 71.8 and price/sales 9.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PEN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Above sector median

+17.5% vs +7.6% peer median

Operating Margin

Below sector median

+13.5% vs +19.4% peer median

P/E

Above sector median

71.8 vs 36.3 peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2026 was reported on Apr 22, 2026, but the surprise data is still limited.

The operating story is still moving forward

Revenue is running at +17.5% and EPS at +1169.4%, with operating margin around 13.5%.

Earnings Reaction Memory

How the stock has tended to move after recent reports.

Across the last 3 reported quarters, the stock averaged +7.4% over the next 5 trading days and finished higher after 2 of those reports.

View quarter-by-quarter reaction table
QuarterEPS ฮ”1D5D20D
2026
Apr 22, 2026
โ€”+0.2%-2.2%-1.5%
2026
Feb 25, 2026
+6.3%+1.0%+0.3%-0.7%
2025
Nov 5, 2025
+4.4%+17.3%+24.3%+30.7%

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

PEN

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

PEN Max Drawdown

-21.44%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for PEN and SPY.

Calendar-year return history is still loading or unavailable.
Penumbra, Inc. logo

Company Overview

Penumbra, Inc.

New York Stock Exchange

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Leadership
Adam Elsesser
IPO Date
Sep 18, 2015
Employees
4.5k
Street Address
One Penumbra Place
Mailing
Alameda, CA, 94502
Region
Alameda, CA, US
Reporting Currency
USD
Investor Line
510 748 3200
Last Updated
May 3, 2026
CIK: 0001321732ISIN: US70975L1070CUSIP: 70975L107
Reports in USDSEC Registered

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
71.8
EV/EBITDA
57.3
Price/Sales
9.1
Price/Book
8.9

Growth

Revenue
+17.5%
EPS
+1169.4%
Free Cash Flow
+18.8%

Profitability

Gross Margin
67.1%
Operating Margin
13.5%
Net Margin
12.7%
ROE
13.4%
ROIC
9.9%

Balance Sheet

Debt/Equity
0.15
Current Ratio
6.64

Earnings Reports

๐Ÿ“… Last reportedApr 22, 2026
PeriodB/MEPSEPS ฮ”RevenueRev ฮ”
โ€”
Apr 22, 26
โ€”
Est 1.11
โ€”
โ€”
Est 371368.3B
โ€”
โ€”
Feb 25, 26
โœ“
1.18
Est 1.11
+6.3%
385385.0B
Est 361866.3B
+6.5%
โ€”
Nov 5, 25
โœ“
0.97
Est 0.93
+4.4%
354685.0B
Est 340951.4B
+4.0%
โ€”
Jul 29, 25
โœ“
0.86
Est 0.81
+6.2%
339455.0B
Est 341345.5B
-0.6%
โ€”
Apr 23, 25
โœ“
0.83
Est 0.66
+25.8%
324140.0B
Est 327275.3B
-1.0%
โ€”
Feb 18, 25
โœ“
0.97
Est 0.88
+10.2%
315518.0B
Est 311633.5B
+1.3%
โ€”
Oct 30, 24
โœ“
0.85
Est 0.69
+23.2%
301039.0B
Est 311573.8B
-3.4%
โ€”
Jul 30, 24
โœ“
0.64
Est 0.56
+14.3%
299403.0B
Est 298360.0B
+0.3%
โ€”
May 7, 24
โœ—
0.41
Est 0.42
-2.4%
278655.0B
Est 274890.0B
+1.4%
โ€”
Feb 22, 24
โœ“
0.76
Est 0.71
+7.0%
284679.0B
Est 286560.0B
-0.7%
โ€”
Nov 2, 23
โœ“
0.67
Est 0.46
+45.6%
270946.0B
Est 265260.0B
+2.1%
โ€”
Aug 1, 23
โœ“
0.43
Est 0.28
+53.6%
261499.0B
Est 253220.0B
+3.3%
โ€”
May 2, 23
โœ“
0.23
Est 0.11
+109.1%
241398.0B
Est 229730.0B
+5.1%
โ€”
Feb 23, 23
โœ“
0.16
Est 0.14
+14.3%
221216.0B
Est 217328.1B
+1.8%
โ€”
Nov 3, 22
โœ“
0.01
Est 0.01
+19.6%
213678.0B
Est 212491.3B
+0.6%
โ€”
Aug 4, 22
โœ“
0.01
Est -0.07
+114.3%
208344.0B
Est 206239.5B
+1.0%

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.